Article Text

Download PDFPDF
Systematic review
Neuraminidase inhibitors produce a small reduction in duration of seasonal flu in children and reduce transmission in affected households, but effects on serious complications are unclear
  1. Karen J Ford,
  2. Claire Waddington
  1. Oxford Vaccine Group, University of Oxford, UK
  1. Correspondence to Karen J Ford
    Oxford Vaccine Group, Clinical Centre for Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LJ, UK; Karen.ford{at}paediatrics.ox.ac.uk

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlAbstract/FREE Full Text

This review addresses the use of antiviral medication in the treatment and prophylaxis of seasonal flu in children. This issue is especially relevant given the current pandemic, in which children have experienced high disease rates and the highest hospitalisation rates.1,,3 This review supplements the 2007 Cochrane review4 and is specific to paediatric patients, consolidating information from reviews focusing on adults.5

The article is a review and meta-analysis of randomised controlled trials of neuraminidase inhibitors in children aged <12 years in the community with either confirmed or clinically suspected flu. A comprehensive search for relevant trial data included electronic databases (Medline and Embase). Primary outcome measures were time to resolution of illness or the incidence …

View Full Text

Footnotes

  • Competing interests None.